Overview
Psoriatic arthritis (PsA) is a chronic inflammatory condition characterized by joint inflammation, often associated with skin psoriasis and other manifestations such as enthesitis and dactylitis. It significantly impacts quality of life and increases cardiovascular risk 136.Diagnosis
Management
Special Populations
Key Recommendations
References
Showing 100 most recent of 379 indexed papers.
1 Marzo-Ortega H, Harrison SR, Fragoulis GE, Michelena X, Macía-Villa C, Aydin SZ et al.. EULAR points to consider and consensus definitions for difficult-to-manage and treatment-refractory psoriatic arthritis. Annals of the rheumatic diseases 2026. link 2 Zabotti A, Piga M, Canzoni M, Nicola CD, Rozza D, Carrara G et al.. Ultrasound for assessing disease activity and structural damage in psoriatic arthritis: the UPsA scores from a multicentre study by the Italian Society of Rheumatology. Annals of the rheumatic diseases 2026. link 3 Llorca J, Ferraz-Amaro I, Moreno-Martínez MJ, Plaza Z, Sánchez-Alonso F, Moreno-Ramos MJ et al.. Disease activity and hyperuricemia predict the development of cardiovascular events in patients with Psoriatic Arthritis: results of the 10-year prospective evaluation in the CARMA cohort. Seminars in arthritis and rheumatism 2026. link 4 Charca LC, Queiro R. Cost-efficiency of imaging strategies for detecting subclinical atherosclerosis in psoriatic arthritis. Clinical rheumatology 2026. link 5 Charca LC, Queiro R. Incremental value of carotid intima-media thickness beyond SCORE2 in identifying subclinical atherosclerosis in PsA. Rheumatology (Oxford, England) 2026. link 6 Tyczyńska K, Krajewski PK, Złotowska A, Szepietowski JC, Świerkot J. Excess cardiovascular morbidity in psoriatic arthritis and cardioprotective effects of biologic dmards: a propensity-matched analysis. Scientific reports 2026. link 7 Leung YY, Bird P, Haroon M, Kishimoto M, Shin K, Mathew AJ et al.. The APLAR Recommendations for the Management of Psoriatic Arthritis. International journal of rheumatic diseases 2025. link 8 James L, Helliwell PS, Hensor EMA, Conaghan PG, Emery P, Coates LC. Tight Control and Radiological Progression: The Radiographic Outcomes of the TICOPA Study. The Journal of rheumatology 2025. link 9 Hojeij B, Koc GH, Luime JJ, Vis M, Coates LC, Kok MR et al.. Psoriatic arthritis flare incidence, definition and risk factors: a systematic review. Rheumatology (Oxford, England) 2025. link 10 Gao S, Xie X, Fan L, Yu L. Efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors for psoriatic arthritis: a network meta-analysis of randomized controlled trials. Frontiers in immunology 2025. link 11 Firdous S, Amjad H, Choudhary MU, Afzal MW, Tayyab RH, Parveen A. Emerging biological therapies for psoriatic arthritis: A systematic review. Medicine 2025. link 12 Wan H, Zhou X, Su J, Xia T, Zhang D. Comparative Efficacy and Safety of Different Regimens of Current JAK Inhibitors in Psoriatic Arthritis: A Network Meta-analysis. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2025. link 13 López-Medina C, Mulder M, Eder L, Husni ME. Advancing Psoriatic Disease Knowledge: Highlights From the GRAPPA 2024 Trainee Symposium. The Journal of rheumatology 2025. link 14 Ruderman EM, Gordon KB. Combined Dermatology/Rheumatology Clinics for Management of Psoriatic Disease: Current State. Rheumatic diseases clinics of North America 2025. link 15 Ribeiro AL, Bittar M, Hamdi W, Mathew AJ, Proft F, Ziade N et al.. Toward Harmonized Recommendations for Psoriatic Arthritis: A Comparative Viewpoint on Global Guidelines. The Journal of rheumatology 2025. link 16 Garcia-Salinas R, Ogdie A, Sommerfleck F, Soriano ER, Ribeiro AL, Avellanal V et al.. Establishing Centers of Excellence for Psoriatic Disease in Latin America: Consensus Recommendations From the REAL-PANLAR Group. The Journal of rheumatology 2025. link 17 Kwan YH, Leung YY. Monitoring psoriatic arthritis in research and clinical practice. Current opinion in rheumatology 2025. link 18 Ribeiro AL, Ayan G, Johnsson HJ, Coras R, Mulder M, Tovar-Bastidas DB et al.. Young-GRAPPA 2024: Progress, Achievements, and Strategic Developments. The Journal of rheumatology 2025. link 19 Cui R, Chen M, Tao YL, Li X, Ding YF, Deng H et al.. Diagnostic delay in patients with psoriatic arthritis from dermatology and rheumatology clinics: a medical record review study. Clinical rheumatology 2025. link 20 Srinivasalu H, Beukelman T, Dennos A, Chen A, Correll C, Ringold S. Juvenile Psoriatic Arthritis Inception Cohort in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: Characteristics and Early Disease Outcomes. The Journal of rheumatology 2025. link 21 Ayan G, Helliwell PS, Lindsay CA, Mease PJ, O'Sullivan D, Pennington SR et al.. GRAPPA 2024: Key Project Advances. The Journal of rheumatology 2025. link 22 Colaco K, Eder L, Grieb SM, Leung YY, Lubrano E, Mease PJ et al.. GRAPPA 2024 Annual Meeting: An Update on Major Project Milestones. The Journal of rheumatology 2025. link 23 Ayan G, Husni ME, Mathew AJ, McInnes IB, Mease PJ. GRAPPA 2024: Innovations in Education Workshop. The Journal of rheumatology 2025. link 24 Gladman DD, Bautista-Molano W, Poddubnyy D, Tillett W, Gottlieb AB. Prologue: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2024 Annual Meeting. The Journal of rheumatology 2025. link 25 Odega UK, Omesiete W, Carlson A, Flowers RH. Characterising Alternative Diagnoses to Psoriatic Arthritis in a Rheumatology-Dermatology Combined Clinic. The Australasian journal of dermatology 2025. link 26 Ribeiro AL, Annfeldt TK, Gladman DD, Tillett W, Orbai AM, Leung YY. Composite Outcome Measures for Psoriatic Arthritis: Project Updates 2024. The Journal of rheumatology 2025. link 27 Singla S, Pennington SR, Hwang ST, Walsh JA. World Café Report From the GRAPPA 2024 Annual Meeting and Trainee Symposium: Exploring GRAPPA's Future Priorities. The Journal of rheumatology 2025. link 28 Briner K, Díaz P, Proft F, Savage LJ. Managing Musculoskeletal Symptoms in Patients With Psoriasis: Who Should Be in the Driver's Seat?. The Journal of rheumatology 2025. link 29 Singla S, Bhatt P, Soriano ER. Global Guidelines for Psoriatic Arthritis Management: A Comparative Analysis. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2025. link 30 James L, Hailey L, Bundy C, Burstow H, Chandler D, Cowper R et al.. Psoriatic Arthritis Priority Setting Partnership: patient- and clinician-informed considerations for future UK health service delivery. Rheumatology (Oxford, England) 2025. link 31 Chandratre P, Sabido-Sauri R, Zhao SS, Abhishek A. Gout, Hyperuricemia and Psoriatic Arthritis: An Evolving Conundrum. Current rheumatology reports 2025. link 32 Romanelli S, Ball GD, Hamade H, Zundell MP, Shin S, Senthilkumaran T et al.. Streamlining Psoriatic Arthritis Screening and Management Using the IDEOM Clinical Framework: A Quality Improvement Initiative. Journal of drugs in dermatology : JDD 2025. link 33 Elman SA, Perez-Chada LM, Armstrong A, Gottlieb AB, Merola JF. Psoriatic arthritis: A comprehensive review for the dermatologist-Part II: Screening and management. Journal of the American Academy of Dermatology 2025. link 34 Kharouf F, Gao S, Pereira D, Cook RJ, Chandran V, Gladman DD. Degenerative Disc Disease in Young Adults With Psoriatic Arthritis. The Journal of rheumatology 2025. link 35 Gossec L, Kerschbaumer A, Ferreira RJO, Aletaha D, Baraliakos X, Bertheussen H et al.. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Annals of the rheumatic diseases 2024. link 36 Fernández-Ávila DG, Bautista-Molano W, Brance ML, Ávila Pedretti MG, Vargas RB, Díaz Coto JF et al.. Pan American League of Associations for Rheumatology Recommendations for the Treatment of Psoriatic Arthritis. The Journal of rheumatology 2024. link 37 Kerschbaumer A, Smolen JS, Ferreira RJO, Bertheussen H, Baraliakos X, Aletaha D et al.. Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. Annals of the rheumatic diseases 2024. link 38 Lambadiari V, Katsimbri P, Kountouri A, Korakas E, Papathanasi A, Maratou E et al.. The Effect of a Ketogenic Diet versus Mediterranean Diet on Clinical and Biochemical Markers of Inflammation in Patients with Obesity and Psoriatic Arthritis: A Randomized Crossover Trial. International journal of molecular sciences 2024. link 39 Mease PJ, Gladman DD, Merola JF, Nash P, Grieve S, Laliman-Khara V et al.. Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis. Rheumatology (Oxford, England) 2024. link 40 Antonazzo IC, Gribaudo G, La Vecchia A, Ferrara P, Piraino A, Cortesi PA et al.. Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: An Updated Systematic Literature Review. PharmacoEconomics 2024. link 41 Mease PJ, Reddy S, Ross S, Lisse JR, Reis P, Griffing K et al.. Evaluating the efficacy of biologics with and without methotrexate in the treatment of psoriatic arthritis: a network meta-analysis. RMD open 2024. link 42 Lembke S, Macfarlane GJ, Jones GT. The worldwide prevalence of psoriatic arthritis-a systematic review and meta-analysis. Rheumatology (Oxford, England) 2024. link 43 McGonagle D, Kavanaugh A, McInnes IB, Kristensen LE, Merola JF, Strober B et al.. Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis. Rheumatology (Oxford, England) 2024. link 44 Maloney A, Dua P, Ahmed GF. Comparative Effectiveness of Bimekizumab in Psoriatic Arthritis: A Model-Based Meta-Analysis of American College of Rheumatology Response Criteria. Clinical pharmacology and therapeutics 2024. link 45 Husni ME, Cheemalavagu S, Armstrong AW, Eder L. Insights and Innovations: A Review of the GRAPPA 2023 Trainee Symposium. The Journal of rheumatology 2024. link 46 Poddubnyy D, Macfarlane GJ, FitzGerald O. Introducing New GRAPPA Projects. The Journal of rheumatology 2024. link 47 Chandran V, Gladman DD, Mease PJ, Eder L, Pennington SR, FitzGerald O et al.. GRAPPA 2023 Collaborative Research Network Meeting. The Journal of rheumatology 2024. link 48 Ayan G, Aydin SZ, Coates LC, Eder L, Gladman DD, Helliwell PS et al.. GRAPPA 2023: Major Projects, Key Advances, and Milestones. The Journal of rheumatology 2024. link 49 Leung YY, Gladman DD, Orbai AM, Tillett W. Composite Outcome Measures for Psoriatic Arthritis: OMERACT and 3 and 4 Visual Analog Scale Progress in 2023. The Journal of rheumatology 2024. link 50 Gunawardana S, Helliwell PS, Kok MR, Vis M, Allard A, Akpabio A et al.. The Development and Validation of a Novel Training Infographic for the Physician Global Visual Analog Scale in Psoriatic Arthritis. The Journal of rheumatology 2024. link 51 Katz A, de Wit M, Lindsay C. GRAPPA 2023 Patient Research Partner (PRP) Network Update: Enhancing PRP Involvement Within GRAPPA. The Journal of rheumatology 2024. link 52 Stolnicki DK, Coates LC, Gollins CE, Koppikar S, Perez-Chada LM, Puig L et al.. Breakout Session and Report Back: Collaboration of Rheumatologists and Dermatologists for the Care of Patients With Psoriatic Disease. The Journal of rheumatology 2024. link 53 de Wit M, Chau J, Grieb SM. How to Involve Patients in GRAPPA Research as Partners. The Journal of rheumatology 2024. link 54 Merola JF, Chakravarty SD, Choi O, Chan D, Gottlieb AB. A clinical review of structural damage in psoriatic arthritis for dermatologists: From pathogenesis to ongoing controversies. Journal of the American Academy of Dermatology 2024. link 55 Gladman DD, FitzGerald O, Armstrong AW, Goel N, Gottlieb AB. Prologue: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2023 Annual Meeting. The Journal of rheumatology 2024. link 56 Urruticoechea-Arana A, Álvarez-Vega JL, García-Vivar ML, Pinto-Tasende JA, García de Yébenes MJ, Carmona L et al.. Core items to be included in a definition of moderate psoriatic arthritis: literature review and expert opinion. Rheumatology international 2024. link 57 Sherri A, Mortada MM, Makowska J, Sokolowska M, Lewandowska-Polak A. Understanding the interplay between psoriatic arthritis and gout: "Psout". Rheumatology international 2024. link 58 Gladman DD, Helliwell PS, Mease PJ. The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Celebrates Its 20th Anniversary. The Journal of rheumatology 2024. link 59 Pinter A, Hofmann M, Kaufmann R, Müller-Stahl J, König A. Screening of psoriatic arthritis by dermatologists - a German nationwide survey. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2024. link 60 Henriques AR, Pimentel-Santos F, Teles de Sousa J, Silva L, Gago L, Emília Santos M et al.. CheckAP: Prevalence of psoriatic arthritis (PsA) and performance evaluation of the EARP questionnaire in the population of Portuguese patients with psoriasis followed in a dermatology setting. ARP rheumatology 2024. link 61 Roseman C, Wallman JK, Jöud A, Schelin M, Einarsson JT, Lindqvist E et al.. Persistent pain and its predictors after starting anti-tumour necrosis factor therapy in psoriatic arthritis: what is the role of inflammation control?. Scandinavian journal of rheumatology 2024. link 62 Colaco K, Lee KA, Akhtari S, Winer R, Chandran V, Harvey P et al.. Derivation and Internal Validation of a Disease-Specific Cardiovascular Risk Prediction Model for Patients With Psoriatic Arthritis and Psoriasis. Arthritis & rheumatology (Hoboken, N.J.) 2024. link 63 Mease PJ, McInnes IB, Tam LS, Rajalingam R, Peterson S, Hassan F et al.. Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis. Rheumatology (Oxford, England) 2023. link 64 Mease P, Setty A, Papp K, Van den Bosch F, Tsuji S, Keiserman M et al.. Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 3-year results from the open-label extension of the randomised controlled phase 3 SELECT-PsA 2 study. Clinical and experimental rheumatology 2023. link 65 Almășan O, Hedeșiu M, Băciuț M, Buduru S, Dinu C. Psoriatic arthritis of the temporomandibular joint: A systematic review. Journal of oral rehabilitation 2023. link 66 Coates LC, van der Horst-Bruinsma IE, Lubrano E, Beaver S, Drane E, Ufuktepe B et al.. Sex-Specific Differences in Patients With Psoriatic Arthritis: A Systematic Review. The Journal of rheumatology 2023. link 67 Laheru D, Antony A, Carneiro S, Di Lernia V, Garg A, Love TJ et al.. Management of Nail Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations. The Journal of rheumatology 2023. link 68 Hailey LH, Amarnani R, Bundy C, McGagh D, James L, Kirtley S et al.. Lifestyle Modifications and Nonpharmacologic Interventions to Improve Outcomes in Psoriatic Arthritis: A Systematic Review. Clinical therapeutics 2023. link 69 Calixto OJ, Meneses-Toro MA, Vera-Parra EC, Bello-Gualtero JM, Romero-Sanchez C, Perdomo SJ. Posttranslational modifications in psoriatic arthritis: A systematic literature review. Autoimmunity reviews 2023. link 70 Soriano ER, Coates LC, Kavanaugh A. GRAPPA 2021 Treatment Recommendations for Psoriatic Arthritis. The Journal of rheumatology 2023. link 71 Kaeley GS, Eder L, Aydin SZ. Developing Ultrasound Measures for the Early Diagnosis of Psoriatic Arthritis. The Journal of rheumatology 2023. link 72 Steinkoenig I, Goel N, Katz A. GRAPPA 2022 Patient Research Partners Network Update: Managing Growth. The Journal of rheumatology 2023. link 73 Khan M, Bressler MY, Markowitz O. Glitter Effects of Nail Art on Optical Coherence Tomography. Cutis 2023. link 74 Siebert S, Pennington SR, Raychaudhuri SP, Chaudhari AJ, Jin JQ, Liao W et al.. Novel Insights From Basic Science in Psoriatic Disease at the GRAPPA 2022 Annual Meeting. The Journal of rheumatology 2023. link 75 Zundell MP, Woodbury MJ, Lee K, Perez-Chada LM, Armstrong AW, Strand V et al.. Report of the Skin Research Workgroups From the IDEOM Breakout at the GRAPPA 2022 Annual Meeting. The Journal of rheumatology 2023. link 76 Leung YY, Tillett W, de Wit M, Orbai AM, Coates LC, FitzGerald O et al.. Initiating Evaluation of Composite Outcome Measures for Psoriatic Arthritis: 2022 Updates From the GRAPPA-OMERACT Working Group. The Journal of rheumatology 2023. link 77 Ng BCK, Jadon D, Adebajo A, Ayan G, Duffin KC, Chandran V et al.. Proceedings of the GRAPPA 2022 Executive Retreat. The Journal of rheumatology 2023. link 78 Kasiem FR, Yamada D, Marin J, Vis M, Tillett W, Hwang ST et al.. GRAPPA 2021 Pilot Grant Award Reports. The Journal of rheumatology 2023. link 79 Torgutalp M, Gladman DD, FitzGerald O, Mease PJ, Poddubnyy D. Project Highlights From the GRAPPA 2022 Annual Meeting: Education Initiatives and Axial Involvement in Psoriatic Arthritis. The Journal of rheumatology 2023. link 80 Skovsgård CH, Laurberg TB, Dige A, Iversen L, Hjuler KF. Arthritis Hit Rate in Patients with Psoriasis Referred for Rheumatology Evaluation. Dermatology (Basel, Switzerland) 2023. link 81 Ng BCK, Jadon D, Behrens F, de Wit M, FitzGerald O, Gladman DD et al.. Proceedings of the Collaborative Research Network Meeting at the GRAPPA 2022 Annual Meeting. The Journal of rheumatology 2023. link 82 Ayan G, Coras R, Grynszpan R, Herrera S, Jethwa H, Johnsson HJ et al.. Young-GRAPPA (Y-GRAPPA) at the 2022 GRAPPA Annual Meeting: One Year in Y-GRAPPA. Where Do We Stand, Where Do We Go?. The Journal of rheumatology 2023. link 83 Exarchou S, Wallman JK, Di Giuseppe D, Klingberg E, Sigurdardottir V, Wedrén S et al.. The National Prevalence of Clinically Diagnosed Psoriatic Arthritis in Sweden in 2017. The Journal of rheumatology 2023. link 84 Gottlieb AB, Armstrong AW, FitzGerald O, Gladman DD. Prologue: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2022 Annual Meeting. The Journal of rheumatology 2023. link 85 Albrecht K, Regierer AC, Strangfeld A, Marschall U, Callhoff J. High burden of polypharmacy and comorbidity in persons with psoriatic arthritis: an analysis of claims data, stratified by age and sex. RMD open 2023. link 86 Erdem Gürsoy D, Gezer HH, Acer Kasman S, Duruöz MT. Associations of Polypharmacy With Clinical Parameters, Function, and Health-Related Quality of Life in Psoriatic Arthritis. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2023. link 87 Rotondo C, Cantatore FP, Cici D, Erroi F, Sciacca S, Rella V et al.. Vitamin D Status and Psoriatic Arthritis: Association with the Risk for Sacroiliitis and Influence on the Retention Rate of Methotrexate Monotherapy and First Biological Drug Survival-A Retrospective Study. International journal of molecular sciences 2023. link 88 Campanholo CB, Maharaj AB, Corp N, Bell S, Costa L, de Vlam K et al.. Management of Psoriatic Arthritis in Patients With Comorbidities: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations. The Journal of rheumatology 2023. link 89 Gezer HH, Acer Kasman S, Duruöz MT. Autonomic dysfunction and cardiovascular risk in psoriatic arthritis. Clinical rheumatology 2023. link 90 Urruticoechea-Arana A, Castañeda S, Otón T, Benavent D, Loza E, Martín-Martínez MA et al.. Prevalence of Metabolic Syndrome in Psoriatic Arthritis: Systematic Literature Review and Results From the CARMA Cohort. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2022. link 91 Wirth T, Balandraud N, Boyer L, Lafforgue P, Pham T. Biomarkers in psoriatic arthritis: A meta-analysis and systematic review. Frontiers in immunology 2022. link 92 Kristensen LE, Keiserman M, Papp K, McCasland L, White D, Lu W et al.. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. Annals of the rheumatic diseases 2022. link 93 Sachdeva M, Abduelmula A, Mufti A, Georgakopoulos JR, Lytvyn Y, Yeung J. A Systematic Review Characterizing Psoriatic Arthritis Onset and Exacerbation in Patients Receiving Biologic Therapy. Journal of cutaneous medicine and surgery 2022. link 94 Barešić M, Smiljanić Tomičević L, Anić B, Mayer M. Successful IL-17A inhibitor cycling in psoriatic arthritis patient: a case report and a literature review. Rheumatology international 2022. link 95 Waddington JC, Coleman O, Mease PJ, Chandran V, O'Sullivan D, FitzGerald O et al.. Basic Science Session 1. Biomarkers for Psoriatic Arthritis Treatment Response and Joint Damage Progression: An Update on 2 Industry-GRAPPA Projects. The Journal of rheumatology 2022. link 96 Behrens F, Rech J, Thaçi D, Zinke S, Rothnie KJ, Oefner Daamen C et al.. High rates of therapeutic changes in patients with psoriatic arthritis receiving treatment with disease-modifying antirheumatic drugs: A cross-sectional study. Modern rheumatology 2022. link 97 Stober C, McInnes IB, Raychaudhuri S, Mease PJ, Pennington SR, Scher JU et al.. Proceedings of the 2021 GRAPPA-Collaborative Research Network (CRN) Meeting. The Journal of rheumatology 2022. link 98 Castillo RL, Yan D, Ashhurst AS, Elliott A, Angioni MM, Scher JU et al.. GRAPPA 2020 Research Award Recipients. The Journal of rheumatology 2022. link 99 Hong C, Fang S, Yeo YW, Koh HY, Lee HY, Low AH et al.. Patient and learner experience in a new set up of a multidisciplinary dermatology-rheumatology clinic care model for psoriatic arthritis. International journal of rheumatic diseases 2022. link 100 Ogdie A, Lindsay CA, Mease PJ, Duffin KC, Rosen CF, Siebert S. Challenges in the Diagnosis and Assessment of Psoriatic Arthritis. The Journal of rheumatology 2022. link